Financial DistressNegative equity and financial distress indicate potential solvency issues, threatening long-term viability and financial flexibility.
Cash Flow ChallengesPersistent negative cash flow suggests ongoing operational challenges, limiting the company's ability to invest in growth and innovation.
Competitive PressureIntense competition from GLP-1 pharmaceuticals could erode market share and hinder revenue growth, impacting long-term competitiveness.